Disclosed herein is a cyanopyrimidine compound of formula (I), wherein R is selected from hydrogen, hydroxy (lower alkyl) group, halogenated (lower alkyl) group or (lower alkoxy)carbonyl-(lower alkyl) group or a salt thereof, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as adenosine A2a receptor agonists and are therefore useful in treating or preventing eye disease such as glaucoma. Specific examples of preferred compounds include: · N-(4-(6-amino-5-cyano-2-((6-(3-oxo-3-(4-(piperidin-4-ylmethyl) piperazin-1-yl) propyl) pyridine-2-yl) methylthio)-pyrimidine-4-yl) phenyl) acetamide, · N-(4-(6-amino-5-cyano-2-((6-(3-(4-((1-(2-hydroxyethyl)-piperidine-4-yl)methyl)piperazin-1-yl)-3-oxopropyl)-pyridine-2-yl)methylthio)pyrimidine-4-yl)phenyl)acetamide, · N-(4-(6-amino-5-cyano-2-((6-(3-(4-((1-(3-hydroxy-propyl)piperidine-4-yl)methyl)piperazin-1-yl)-3-oxopropyl)-pyridine-2-yl)methylthio)pyrimidine-4-yl)phenyl)acetamide, · N-(4-(6-amino-5-cyano-2-((6-(3-(4-((I-(2-fluoroethyl)piperidine-4-yl)methyl)piperazin-1-yl)-3-oxopropyl)pyridine-2-yl)methylthio)pyrimidine-4-yl)phenyl)acetamide, and · N-(4-(6-amino-5-cyano-2-( (6-(3-(4-( (1-(2-methoxy-carbonylethyl)piperidine-4-yl)methyl)piperazin-l-yl)-3-oxopropyl) pyridine-2-yl)methylthio) pyrimidine-4-yl)phe nyl)-acetamide.
